



| Ticket #: | Request Date: | Request Time: |
|-----------|---------------|---------------|
| | • | |

Procrit® Prior Authorization Request Form (Page 1 of 3)

| | | | RE UPDATED FREQUEN | | | |
|---|---|---|--|---|---------------------------------------|--|
| Member Information (required) | | Provider Information (required) | | | | |
| Member Name: | | • • • | Provider Name: | | · · · · · · · · · · · · · · · · · · · | |
| Insurance ID#: | | | NPI#: | | Specialty: | |
| Date of Birth: | | | Office Phone: | | | |
| Street Address: | | | Office Fax: | | | |
| City: | State: | Zip: | Office Street Add | dress: | | |
| Phone: | - I | 1 | City: | State: | Zip: | |
| | | Medication | Information (req | uired) | | |
| Medication Name: | | Strength: | | Dosage Form: | | |
| ☐ Check if requesting | g brand | | Directions for Us | se: | | |
| ☐ Check if request is | s for continuation | of therapy | | | | |
| ☐ Anemia in HIV-in: ☐ Anemia in patient ☐ Preoperative use ☐ Other diagnosis: | ronic kidney disea patients on chemo tis C virus (HCV)-ir fected patients ts with myelodyspla for reduction of all | se otherapy nfected patients due to ri astic syndrome (MDS) | | rith interferon or p g surgery | peg-interferon | |
| Is the patient on dialy Has the patient beer Please provide the h Hemoglobin (Hgb) Does the rate of hem Is the goal of therapy Reauthorization: Has the patient beer Is there a decrease i Has the hemoglobin Document the hemoglobin Hgb: Hgb: | ysis? Yes N n evaluated for ade nemoglobin (Hgb) a noglobin decline ind y to reduce the risk n evaluated for ade n the need for block increased greater oglobin (Hgb) and h Hct: Hct: | quate iron stores? Yeard hematocrit (Hct) level Date: dicate the likelihood of real of alloimmunization and quate iron stores? Yeard transfusion with Procrithan or equal to 1g/dL fr | es □ No els collected within 30 da Hematocrit (Hct): equiring a red blood cell d/or other RBC transfusion es □ No rit therapy? □ Yes □ No rom pre-treatment level? ollected from the past 3 in | Date (RBC) transfusion pon-related risks? | te: on? □ Yes □ No | |

Procrit® Prior Authorization Request Form (Page 2 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

| For anemia in cancer patients on chemotherapy, answer the following: |
|--|
| Have other causes of anemia been ruled out? ☐ Yes ☐ No |
| Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within <i>the prior two weeks</i> of this request: |
| Hemoglobin (Hgb): Date: Hematocrit (Hct): Date: |
| Has the patient been evaluated for adequate iron stores? ☐ Yes ☐ No |
| Is the cancer a non-myeloid malignancy? Yes No |
| Is the patient concurrently on chemotherapy? \(\begin{align*} \text{Yes} \\ \begin{align*} \text{No} \\ \te |
| Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? ☐ Yes ☐ No |
| Is the anemia caused by cancer chemotherapy? Yes No |
| Reauthorization: |
| Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within <i>the prior two weeks</i> of this request: |
| Hemoglobin (Hgb): Date: Hematocrit (Hct): Date: |
| Is there a decrease in the need for blood transfusion with Procrit therapy? Yes No |
| Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? Yes No |
| Is the patient concurrently on chemotherapy? \(\begin{align*} \text{Yes} \\ \begin{align*} \text{No} \\ Virily 1.0.5 P.V. 1. |
| Will the patient be receiving concomitant chemotherapy for a minimum of 2 months? ☐ Yes ☐ No |
| Is the anemia caused by cancer chemotherapy? Yes No |
| For anemia in HCV-infected patients due to ribavirin in combination with interferon or peg-interferon, answer the following: |
| Does the patient have a diagnosis of hepatitis C virus (HCV) infection? Yes No |
| Has the patient been evaluated for adequate iron stores? Yes No |
| Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within 30 days of this request: |
| Hemoglobin (Hgb): Date: Hematocrit (Hct): Date: |
| Is the patient receiving ribavirin? Yes No |
| Is the patient receiving interferon alfa-2b, interferon alfacon-1, peginterferon alfa-2b, or peginterferon alfa-2a? 🗖 Yes 🗖 No |
| Reauthorization: |
| Is there a decrease in the need for blood transfusion with Procrit therapy? No |
| Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? Yes No |
| Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months: |
| Hgb: Hct: Date: |
| Hgb: Hct: Date: |
| Hgb: Hct: Date: |
| For anemia in HIV-infected patients, answer the following: |
| Has the patient been evaluated for adequate iron stores? Yes No |
| Please provide the hemoglobin (Hgb) and hematocrit (Hct) levels collected within <i>30 days</i> of this request: |
| Hemoglobin (Hgb): Date: Hematocrit (Hct): Date: |
| Is the serum erythropoietin level less than or equal to 500 mU/mL? Yes No |
| Is the patient receiving zidovudine (AZT) therapy? |
| Does the patient have a diagnosis of HIV infection? Yes No |
| Reauthorization: |
| Is there a decrease in the need for blood transfusion with Procrit therapy? \(\begin{align*} \text{Yes} \\ \\ \ext{D} \text{No} \end{align*} |
| Has the hemoglobin increased greater than or equal to 1g/dL from pre-treatment level? Yes No |
| Document the hemoglobin (Hgb) and hematocrit (Hct) levels collected from the past 3 months: |
| Hgb: Hct: Date: |
| Hgb: Hct: Date: |
| Hgb: Hct: Date: |
| |

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Procrit_Comm_5/2019

Procrit® Prior Authorization Request Form (Page 3 of 3) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

| For preoperati | ve use for reduction of a | allogeneic blood transfusior | n in patients undergoing surgery, answer the followin | ng: |
|----------------------------------|------------------------------|---------------------------------|--|-------------|
| Is the patient so | heduled to undergo elect | ive, non-cardiac, non-vascular | ır surgery? ☐ Yes ☐ No | |
| Is the hemoglob | oin (Hgb) > 10 to ≤ 13 g/dl | L? 🛘 Yes 🚨 No | | |
| Is the patient at | high risk for perioperative | e transfusions? 🛭 Yes 📮 No | 0 | |
| Is the patient wi | illing or able to donate aut | tologous blood pre-operatively | y? □ Yes □ No | |
| Has the patient | been evaluated for adequ | uate iron stores? 🛚 Yes 🔲 N | No | |
| For anemia in | patients with myelodysr | plastic syndrome (MDS), ans | swer the following: | |
| Is the serum ery | ythropoietin level less than | n or equal to 500 mU/mL? | Yes 🗖 No | |
| Does the patien | it have transfusion-depen | dent MDS? 🗆 Yes 🗀 No | | |
| Has the patient | been evaluated for adequ | uate iron stores? 🛚 Yes 🔲 N | No | |
| Reauthorizatio | n: | | | |
| Is there a decre | ase in the need for blood | transfusion with Procrit therap | py? ☐ Yes ☐ No | |
| Has the hemog | lobin increased greater th | an or equal to 1g/dL from pre- | e-treatment level? Yes No | |
| Document the | hemoglobin (Hgb) and he | matocrit (Hct) levels collected | from the past 3 months: | |
| | | Date: | · | |
| | | Date: | | |
| | | Date: | | |
| Are there any other this review? | er comments, diagnoses, s | ymptoms, medications tried or | r failed, and/or any other information the physician feels is in | mportant to |
| | | | | |
| Authorized Med | ical Signature: | | | |
| Telephone: | | | Date: | |

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

Please note: This request may be denied unless all required information is received.